| Literature DB >> 21459676 |
Morten Ruhwald1, Jose Dominguez, Irene Latorre, Monica Losi, Luca Richeldi, Maria Bruna Pasticci, Rosanna Mazzolla, Delia Goletti, Ornella Butera, Judith Bruchfeld, Hans Gaines, Irini Gerogianni, Tamara Tuuminen, Giovanni Ferrara, Jesper Eugen-Olsen, Pernille Ravn.
Abstract
IP-10 has potential as a diagnostic marker for infection with Mycobacterium tuberculosis, with comparable accuracy to QuantiFERON-TB Gold In-Tube test (QFT-IT). The aims were to assess the sensitivity and specificity of IP-10, and to evaluate the impact of co-morbidity on IP-10 and QFT-IT. 168 cases with active TB, 101 healthy controls and 175 non-TB patients were included. IP-10 and IFN-γ were measured in plasma of QFT-IT stimulated whole blood and analyzed using previously determined algorithms. A subgroup of 48 patients and 70 healthy controls was tested in parallel with T-SPOT.TB IP-10 and QFT-IT had comparable accuracy. Sensitivity was 81% and 84% with a specificity of 97% and 100%, respectively. Combining IP-10 and QFT-IT improved sensitivity to 87% (p < 0.0005), with a specificity of 97%. T-SPOT.TB was more sensitive than QFT-IT, but not IP-10. Among non-TB patients IP-10 had a higher rate of positive responders (35% vs 27%, p < 0.02) and for both tests a positive response was associated with relevant risk factors. IFN-γ but not IP-10 responses to mitogen stimulation were reduced in patients with TB and non-TB infection. This study confirms and validates previous findings and adds substance to IP-10 as a novel diagnostic marker for infection with M. tuberculosis. IP-10 appeared less influenced by infections other than TB; further studies are needed to test the clinical impact of these findings.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21459676 DOI: 10.1016/j.tube.2011.01.001
Source DB: PubMed Journal: Tuberculosis (Edinb) ISSN: 1472-9792 Impact factor: 3.131